Years of translational research have successfully improved treatment outcomes for common dermatological conditions such as ...

The gut microbiome comprises the trillions of bacteria and other microorganisms that live in our digestive tracts, and it has ...

A new study found no significant benefit in adding low-dose oral glucocorticoids to immunosuppressive therapy for improving skin fibrosis in patients with early diffuse cutaneous systemic ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development ...

A woman dubbed 'the world's most beautiful traffic warden' has shared a horrible health battle she has had to go through ...

Explore a rare case of systemic mastocytosis in a young adult, highlighting its role in unexplained osteoporosis and the need ...

Health charity Scleroderma & Raynaud's UK (SRUK) is urging the public to take a 60-second online test to find out if they may ...

“Broken skin barriers” are real. They’re the subject of great interest from " skinfluencers " on TikTok, but they’re also ...

Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse clinical outcomes.

The mechanisms that drive the diverse disease manifestations and increased cancer risk associated with systemic sclerosis are unclear. Investigating the genomic alterations observed in patients ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not.